Description: Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative rare diseases. The company offers heat stock proteins that focuses on the treatment of neurodegenerative diseases by harnessing the cell protective properties of the heat shock response, which protects cells from the accumulation of misfolded proteins, aggregated proteins, and dysfunctional lysosomes. Its lead candidate is the Arimoclomol, which is in clinical development for diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, and Inclusion Body Myositis. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.
Home Page: www.orphazyme.com
Ole MaalOees Vej 3
Copenhagen,
2200
Denmark
Phone:
45 39 17 82 72
Officers
| Name | Title |
|---|---|
| Mr. Anders Fink Vadsholt M.B.A., M.Sc., MBA | CEO, CFO & Director |
| Jennifer Jean McCann | Pres of Orphazyme US, Inc. |
Exchange: CO
Country: DK
Currency: Danish krone (kr)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.4696 |
| Price-to-Sales TTM: | 1.0463 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 2 |